Introduction
cResponse™ is an ex vivofunctional platform that assess and predicts the effectiveness of single and multidrug chemotherapy, immunotherapy as well as innovative biological treatments on the tumour tissue.
One of the primary challenges in selecting appropriate cancer treatment is the heterogeneity of tumours. It is challenging to forecast the best available treatment for a given patient because tumours can differ in their genetic composition, tumour microenvironment and how they react to treatments. (source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4024849/)
By analyzing live tumour cells in a controlled environment, cResponse™ helps healthcare professionals to identify the best course of treatment for each patient. This reduces the trial-and-error methods and improves outcomes.
The innovative method bridges the gap between molecular profiling and actual treatment efficacy by giving oncologist practical information into how each patient’s tumour responds to various treatment regimes.
Why choose cResponse™?
- Preserving 3D Tumour microenvironment (TME):
- cResponse™ platform uniquely preserves 3D TME structure for accurate therapy simulation.
- Functional Precision Medicine:
- Provides a real-time evaluation of the effectiveness of treatment by directly measuring how live tumour cells react to treatments.
- Personalized Treatment:
- Reduces needless side effects and improves patient outcomes by identifying the treatments that are most likely to be effective for each patient.
- Molecular Profiling and IHC staining included:
- Integrates genomic and IHC staining to offer a better understanding of tumour biology and treatment response.
- Faster Decision-Making:
- Speeds up treatment planning by providing useful insights in a timely manner.
- Cost-Effective:
- Lowers the financial costs that are associated with ineffective treatments.
Applications
cResponse is beneficial for:
- Treatment selection: Identifying the most suitable therapies tailored to each patient’s needs.
- Treatment Resistance: Detecting new resistance to already existing treatments and suggesting alternatives.
- Research and Development: Transforming pharma development and bringing better drugs faster to market with real-world tumour report.
- Clinical Trials: Matching patients with potentially beneficial treatments or experimental drugs.
How does cResponse work?
The cResponse™ an ex vivo functional platform that combines a functional assessment of tumour sensitivity to various treatment regimens with a rapid genomic sequencing assay, which can aid oncologists in selecting optimal treatments for patients:
Workflow
- Sample collection: Fresh tumour tissue from surgery or biopsy are collected from the patient
- Ex Vivo Testing:
- Genomic testing: Some of the tissue sections undergo rapid genomic sequencing to help identify tumour-specific genomic alterations that may be targeted by specific anticancer drugs.
- Drug testing: Tissue sections are treated with a drug or treatment regimen according to the oncologist’s request which are selected before the tumour tissue arrives at the laboratory.
- Histological staining: The tissue sections undergo histological processing and evaluation of the drugs’ effectiveness according to various criteria.
- Data Analysis: viability of tumour cells and their response patterns are examined to determine the most effective treatment options.
- Result report: A comprehensive report is provided, detailing suggested treatments and additional insights.
Research and publications
The cResponse™ platform is supported by extensive research and clinical data:
- Clinical studied across 12 international centers involving 54 patients demonstrated that the The cResponse™ platform achieved 90% sensitivity and 91.6% specificity.
- The cResponse™ platform was evaluated in a Phase 2 clinical trial presented at the American Association for Cancer Research (AACR) 2023 conference. Clinical study involving 49 patients across multiple international centers showed cResponse™ achieved a sensitivity of 96.5% and a specificity of 90% in predicting therapeutic efficacy.
- The study by Woll et al. (2023) highlights the cResponse™ platform’s ability to predict patient-specific treatment responses by preserving the tumour microenvironment in a 3D ex vivo system. This approach demonstrated strong potential for guiding personalized cancer therapy.
